C97 Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.99 |
| 52 Week High | US$1.60 |
| 52 Week Low | US$0.85 |
| Beta | -0.85 |
| 11 Month Change | -13.48% |
| 3 Month Change | -37.03% |
| 1 Year Change | -12.41% |
| 33 Year Change | -86.55% |
| 5 Year Change | 28.04% |
| Change since IPO | -8.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| C97 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.0% | -1.0% | -0.02% |
| 1Y | -12.4% | -7.3% | 8.2% |
Return vs Industry: C97 underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: C97 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| C97 volatility | |
|---|---|
| C97 Average Weekly Movement | 10.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C97's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C97's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 155 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
| C97 fundamental statistics | |
|---|---|
| Market cap | €32.50m |
| Earnings (TTM) | -€39.65m |
| Revenue (TTM) | €7.03m |
4.4x
P/S Ratio-0.8x
P/E RatioIs C97 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C97 income statement (TTM) | |
|---|---|
| Revenue | US$7.32m |
| Cost of Revenue | US$3.71m |
| Gross Profit | US$3.61m |
| Other Expenses | US$44.89m |
| Earnings | -US$41.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 49.30% |
| Net Profit Margin | -563.91% |
| Debt/Equity Ratio | 0% |
How did C97 perform over the long term?
See historical performance and comparison